Biospace Med Expands European Market Penetration with ‘EOS’, Which Cuts Radiation up to 90% vs. Conventional X-Rays
Company seeks to establish EOS as the ‘gold standard’ among Europe’s leading pediatric and orthopedic imaging centers
CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)– Biospace med announced today that it continues to penetrate the European market with its CE Marked ‘EOS’ x-ray imager—the world’s first ultra-low-dose x-ray technology—recently adding two new regions of coverage in France: West (Brest University Hospital) and North (Lille University Hospital). These two recent installations are expanding national coverage with EOS in France as the Company already has systems operating in Paris, Lyon, Marseille, Bordeaux, and Nice.
EOS can capture head-to-toe images of patients in a standing, weight-bearing position with a dramatic reduction in radiation dose—up to 10 times less than a conventional x-ray and up to 1000 times less than a CT (Computed Tomography) scan. Additionally, EOS images are designed to provide sharp detail and empower physicians to better diagnose and plan an effective course of treatment.
“We are extremely pleased to announce new sales of our ultra-low-dose EOS x-ray imager into new markets in France,” said Marie Meynadier, Ph.D., chief executive officer of Biospace med. “Combined with our recently announced new customers in two new regions of the United States, and in The Netherlands, we are making significant headway in persuading healthcare institutions which are still imaging patients with a conventional digital x-ray that there is a better way—not only for them but also for their patients. EOS uses dramatically less radiation than a conventional x-ray or CT scan and thus represents an extraordinary enhancement in musculoskeletal imaging—as all other imaging modalities deliver a substantial dose of radiation to the patient,” added Dr. Meynadier.
About Biospace med
Biospace med was founded on a unique partnership between Nobel Prize-winning physicist Georges Charpak, Ph.D., and a team of biomedical engineers, orthopedic surgeons and radiologists who have developed a complete orthopedic imaging solution. The Company’s lead product, EOS ultra-low-dose 2D/3D x-ray imager, allows full-body imaging of patients in a weight-bearing position that enables global assessment of balance and posture. EOS is a total solution in orthopedic imaging now available in the U.S. since receiving FDA 510(k) clearance. The Company has corporate headquarters in Cambridge, Mass., and Paris, as well as an office in Montreal, and is targeting a $2 billion orthopedic imaging marketplace. The Company’s U.S. headquarters is located at 185 Alewife Brook Parkway, #410, Cambridge, Mass. (toll free: +1-866-933-5301). Learn more at www.biospacemed.com.
